Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T16:03:51.919Z.
Calculation as of: 2026-10-06T16:03:51.919Z.
Quote observation: 2026-10-06T16:00:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7407100010b300fbb3ac755cbb3002365509bca003114ec09b48135e475ff23c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$10.52M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$11.30M
EV/EBIT Ratio
N/A
TTM Avg
13.02x
3Y Avg
13.02x
5Y Avg
13.02x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lisata Therapeutics, Inc. (LSTA) | $10.93M | N/A | N/A | N/A | N/A |
| Caring Brands, Inc. (CABR)vs › | $10.68M | N/A | N/A | N/A | N/A |
| Cerenome, Inc. (CNSY)vs › | $11.36M | N/A | N/A | N/A | N/A |
| BioVie Inc. (BIVI)vs › | $11.08M | N/A | N/A | N/A | N/A |
| Lifeward Ltd. (LFWD)vs › | $10.55M | N/A | N/A | N/A | N/A |
| Polyrizon Ltd. (PLRZ)vs › | $10.53M | N/A | N/A | N/A | N/A |
| CytoMed Therapeutics Limited (GDTC)vs › | $10.52M | N/A | N/A | N/A | N/A |
| Satellos Bioscience Inc. (MSLE)vs › | $10.44M | N/A | N/A | N/A | N/A |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.30M | N/A | 13.02x | 13.02x | 13.02x |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.44M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
